Sandoz enters a strategic collaboration with Shanghai Henlius Biotech on up to 10 biosimilar assets, with an initial agreement for three biosimilar drugs in early development stages. The three initial biosimilars are for evolocumab (cholesterol treatment), belimumab (lupus), and cetuximab (colorectal cancer). Sandoz gains global commercialization rights outside China, while Henlius handles development and manufacturing. Sandoz will pay up to about $77 million upfront, with total potential consideration of up to $322 million in milestone payments. The deal expands Sandoz’s biosimilar pipeline and aims to improve global patient access to high‑quality biosimilar medicines. Sources: Sandoz to license three biosimilar drugs from Shanghai Henlius ... Henlius and Sandoz Enter Strategic Collaboration to Unlock Global ... Sandoz to license three biosimilar drugs from Shanghai ... Shanghai Henlius Biotech, Inc. Sandoz announces strategic collaboration with Henlius on up to 10...
- Get link
- X
- Other Apps